Federal Rule Moves Approved Marijuana Medicines to Schedule III

The Justice Department places FDA-approved drug products containing marijuana in Schedule III and subjects their import and export to federal permit requirements. The rule also creates expedited DEA registration for qualifying state medical marijuana licensees seeking to manufacture, distribute, or dispense marijuana under federal law.

Clinical & Patient Impact

Schedule III status may reduce research and prescribing barriers for FDA-approved marijuana medicines, while expedited registration could bring some state-licensed medical cannabis operations into closer alignment with federal law. It does not automatically convert every state cannabis product into an FDA-approved prescription drug or eliminate applicable DEA, FDA, and state requirements.